2 FTSE 100 stocks I’d sell in June

G A Chester explains why he believes the valuations of these two FTSE 100 (INDEXFTSE:UKX) stocks are far too high.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Accountancy software group Sage (LSE: SGE) and pharma firm AstraZeneca (LSE: AZN) are two FTSE 100 stocks whose valuations are far too high, in my opinion. Here’s why I’d be happy to sell these stocks today, and look for lower-rated businesses with greater margins of safety.

Sagging Sage

Investors in Sage endured a torrid 2018. The share price reached highs of over 820p in the first weeks of the year, but by late October had slumped to a low of 525p. However, we’ve since seen a massive rally. This has taken the price back towards 800p (790p, as I’m writing).

When the shares were last at this level, Sage had guided on an acceleration in organic revenue growth to 8% (from 6.6%), moving towards a medium-term target of 10%, while maintaining an organic operating margin of at least 27%.

Should you invest £1,000 in TUI right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if TUI made the list?

See the 6 stocks

The acceleration hasn’t materialised, with 6.6% posted in fiscal 2018 and 6.2% in the first half of this year. Meanwhile, the current margin target is 23% to 25%, because the new chief executive has ramped up investment in product and innovation.

Competition

Sage was late to recognise an industry shift towards cloud-based solutions, which are easier to install and update. As such, some cloud-only rivals have superior offerings at lower prices. This makes it hard for Sage to win new customers without reducing its pricing and continuing to invest in product and innovation. Because of this, I think the old targets for revenue growth (10%) and margin (at least 27%) are likely gone for good.

In the circumstances, a rating of 26 times current-year forecast earnings looks far too rich to me, and a prospective dividend yield of 2.2% doesn’t set my pulse racing. I see better value elsewhere in the market.

Rotten core

AstraZeneca’s shares hit a new all-time high earlier this month, and a current price of 6,378p is only a couple of percentage points off the peak. On the face of it, the rating isn’t as high as Sage’s. Its guidance for current-year core earnings per share of $3.50 to $3.70 gives a multiple of 22.5 (at the guidance midpoint and current exchange rates). However, I take issue with the company’s ‘core’ earnings measure.

In recent years, it’s been disposing of older drugs it no longer considers core. However, the one-time-only profits on these non-core asset disposals are included in its ‘core’ earnings numbers. I calculate this has boosted annual core earnings by between 20% and 33%. As such, I put the real forward earnings multiple at upwards of 28 (versus 22.5 on the company’s ‘core’ guidance).

Under pressure

AstraZeneca has maintained an annual dividend of $2.80 (220.5p at current exchange rates) for a good number of years, giving a running yield of 3.5% at today’s share price. However, operating cash flow has barely been enough to cover capital investment over the last five years. Effectively, the company has been borrowing money to pay shareholders.

Two days after paying out the latest dividend ($2.4bn gross), the board announced a placing to raise $3.5bn. Part of the purpose of this was “to improve the company’s overall balance-sheet strength and liquidity.”

As such, the board’s ‘core’ earnings measure masks not only what I consider to be a sky-high real earnings multiple, but also an under-pressure dividend and balance sheet. Like Sage, AstraZeneca does have growth prospects, but again I feel the current valuation is far too rich.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in TUI right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if TUI made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca and Sage Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s why I’m waiting for a lower Rolls-Royce share price to buy

After a storming couple of years for the Rolls-Royce share price, this writer explains why he's holding off on making…

Read more »

Investing Articles

Could this FTSE 100 stalwart turn my Stocks and Shares ISA into a passive income machine?

Tesco has been a resilient part of the FTSE 100 since 1996. But should Stephen Wright look to make it…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

These are my top 3 defensive shares to buy in 2025!

Mark Hartley considers three shares he feels could provide stability if markets are volatile -- and if he wants to…

Read more »

Investing Articles

After rising 2,081%, has Nvidia stock peaked?

Our writer likes the chipmaker's business but is less enthusiastic about the current Nvidia stock price. Here's how he's approaching…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

This UK share is already up 27% in 2025! I think it could go even higher

The second upbeat trading update in under a month has sent this UK share higher today. Our writer explains why…

Read more »

Investing Articles

How much would an investor need in a Stocks and Shares ISA to earn £2,000 a month in passive income?

UK residents can use a Stocks and Shares ISA to generate tax-free income. Dr James Fox details a stock that…

Read more »

Road trip. Father and son travelling together by car
Investing Articles

£20,000 invested in Tesla shares just 3 months ago is now worth…

Tesla shares have been on an absolute tear in recent months. Is it time for this Fool to just hold…

Read more »

Investing Articles

If a 30-year-old put £150 a week in S&P 500 shares, here’s what they could have by retirement

A regular investment in the S&P 500 index could help a 30-year-old build a massive multi-million pound portfolio. Ben McPoland…

Read more »